Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy
Annabelle Ballesta1, Jonathan Lopez, Nikolay Popgeorgiev
1BANG project team, INRIA Rocquencourt, Le Chesnay, Yvelines, France. annabelle.ballesta@inria.fr
Plos Computational Biology
|April 18, 2013
Summary
Targeting cancer cells with deregulated Src tyrosine kinase activity may involve downregulating Bax. This strategy leverages Bax overexpression in cancer cells to induce apoptosis, offering a novel therapeutic approach.
Area of Science:
- Oncology
- Biochemistry
- Systems Biology
Background:
- Src tyrosine kinases are frequently deregulated in cancers, promoting tumorigenesis and tumor progression.
- Src activation confers resistance to apoptosis by accelerating Bik degradation and impairing Bax activation.
- Cancer cells often exhibit resistance to apoptosis, necessitating novel therapeutic strategies.
Purpose of the Study:
- To design optimal anticancer therapeutic strategies using a systems biomedicine approach.
- To investigate the role of Src in apoptosis resistance and identify potential therapeutic targets.
- To develop and validate novel therapeutic strategies for Src-driven cancers.
Main Methods:
- Development and fitting of mathematical models for Bik kinetics and the mitochondrial apoptosis pathway.
- Experimental validation of model predictions using Src-transformed and parental fibroblasts.
- Comparative analysis of apoptosis regulation in Src-transformed versus parental cells.
Main Results:
- Src inhibitors can overcome apoptosis resistance in Src-transformed cells.
- Inhibitors of antiapoptotic Bcl-2 proteins are ineffective when resistance stems from a lack of apoptosis accelerators.
- Bax overexpression in Src-transformed cells was identified as a key factor for therapeutic targeting.
Conclusions:
- Targeting Bax, rather than antiapoptotic proteins, is a promising strategy for Src-driven cancers.
- Downregulating Bax to specific levels can selectively induce apoptosis in cancer cells with deregulated Src.
- This study presents an unexpected yet validated therapeutic approach using Bax inhibitors for Src-targeted cancer therapy.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...